Refractory Epilepsy- Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Refractory Epilepsy- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Epilepsy pipeline landscape is provided which includes the disease overview and Refractory Epilepsy treatment guidelines. The assessment part of the report embraces, in depth Refractory Epilepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Refractory Epilepsy Understanding
Patients with epilepsy whose seizures do not successfully respond to anti-seizure drug therapy are considered to have Refractory Epilepsy. This condition is also referred to as intractable, drug-resistant, or pharmacoresistant epilepsy. Refractory or uncontrolled epilepsy is a heavy burden. According to Epilepsy Foundation, in the United States, approximately 3.4 million people live with epilepsy, and over 150,000 new cases are diagnosed each year. One in 26 people will develop epilepsy at some point in their life. Epilepsy doesn’t discriminate. If affects children and adults, men and women, and people of all races, religions, ethnic backgrounds, and social classes. While epilepsy is most often diagnosed either in childhood or after the age of 65, it can occur at any age. The common triggers of epilepsy include Sleep deprivation, overtired, not sleeping well, not getting enough sleep, flashing bright lights or patterns, alcohol consumption, stress, low blood sugar, etc.
Refractory Epilepsy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Refractory Epilepsy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Refractory Epilepsy pipeline report covers 8+ companies. Some of the key players include UCB Biopharma (Padsevonil (UCB0942)), Aquestive Therapeutics (AQST-203), PTC Therapeutics (Ataluren) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Refractory Epilepsy Analytical Perspective by DelveInsight
Scope of the report
"Refractory Epilepsy- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Epilepsy pipeline landscape is provided which includes the disease overview and Refractory Epilepsy treatment guidelines. The assessment part of the report embraces, in depth Refractory Epilepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Refractory Epilepsy Understanding
Patients with epilepsy whose seizures do not successfully respond to anti-seizure drug therapy are considered to have Refractory Epilepsy. This condition is also referred to as intractable, drug-resistant, or pharmacoresistant epilepsy. Refractory or uncontrolled epilepsy is a heavy burden. According to Epilepsy Foundation, in the United States, approximately 3.4 million people live with epilepsy, and over 150,000 new cases are diagnosed each year. One in 26 people will develop epilepsy at some point in their life. Epilepsy doesn’t discriminate. If affects children and adults, men and women, and people of all races, religions, ethnic backgrounds, and social classes. While epilepsy is most often diagnosed either in childhood or after the age of 65, it can occur at any age. The common triggers of epilepsy include Sleep deprivation, overtired, not sleeping well, not getting enough sleep, flashing bright lights or patterns, alcohol consumption, stress, low blood sugar, etc.
Refractory Epilepsy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Refractory Epilepsy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Refractory Epilepsy pipeline report covers 8+ companies. Some of the key players include UCB Biopharma (Padsevonil (UCB0942)), Aquestive Therapeutics (AQST-203), PTC Therapeutics (Ataluren) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Refractory Epilepsy Analytical Perspective by DelveInsight
- In-depth Refractory Epilepsy Commercial Assessment of products
- Refractory Epilepsy Clinical Assessment of products
Scope of the report
- The Refractory Epilepsy report provides an overview of therapeutic pipeline activity for Refractory Epilepsy across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Refractory Epilepsy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Refractory Epilepsy Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Refractory Epilepsy
- Establish a comprehensive understanding of the current pipeline scenario across Refractory Epilepsy to formulate effective R&D strategies
- Assess challenges and opportunities that influence Refractory Epilepsy R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Refractory Epilepsy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Refractory Epilepsy to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. REFRACTORY EPILEPSY
2.1. Refractory Epilepsy Disease Overview
2.2. Refractory Epilepsy History
2.3. Refractory Epilepsy Symptoms
2.4. Refractory Epilepsy Causes
2.5. Refractory Epilepsy Pathophysiology
2.6. Refractory Epilepsy Diagnosis
2.6.1. Diagnostic Guidelines
3. REFRACTORY EPILEPSY CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. REFRACTORY EPILEPSY - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Refractory Epilepsy companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Refractory Epilepsy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Refractory Epilepsy Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. REFRACTORY EPILEPSY PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. REFRACTORY EPILEPSY-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Padsevonil (UCB0942)- UCB Biopharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. AQST-203- Aquestive Therapeutics
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. Ataluren- PTC Therapeutics
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. REFRACTORY EPILEPSY KEY COMPANIES
8.1. UCB Pharma
8.2. Bial
8.3. Threshold Pharmaceuticals
8.4. Aquestive Therapeutics
8.5. Eisai
8.6. Marinus Pharmaceuticals
8.7. GW Pharmaceuticals
8.8. PTC Therapeutics
8.9. UCB Pharma
9. REFRACTORY EPILEPSY KEY PRODUCTS
9.1. Padsevonil
9.2. Seletracetam
9.3. Eslicarbazepine acetate
9.4. AQST-203
9.5. 2-Deoxy-D-glucose
9.6. Perampanel
9.7. Ganaxolone
9.8. Cannabidiol
9.9. Ataluren
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. REFRACTORY EPILEPSY - UNMET NEEDS
12. REFRACTORY EPILEPSY - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. REFRACTORY EPILEPSY
2.1. Refractory Epilepsy Disease Overview
2.2. Refractory Epilepsy History
2.3. Refractory Epilepsy Symptoms
2.4. Refractory Epilepsy Causes
2.5. Refractory Epilepsy Pathophysiology
2.6. Refractory Epilepsy Diagnosis
2.6.1. Diagnostic Guidelines
3. REFRACTORY EPILEPSY CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. REFRACTORY EPILEPSY - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Refractory Epilepsy companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Refractory Epilepsy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Refractory Epilepsy Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. REFRACTORY EPILEPSY PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. REFRACTORY EPILEPSY-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Padsevonil (UCB0942)- UCB Biopharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. AQST-203- Aquestive Therapeutics
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. Ataluren- PTC Therapeutics
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. REFRACTORY EPILEPSY KEY COMPANIES
8.1. UCB Pharma
8.2. Bial
8.3. Threshold Pharmaceuticals
8.4. Aquestive Therapeutics
8.5. Eisai
8.6. Marinus Pharmaceuticals
8.7. GW Pharmaceuticals
8.8. PTC Therapeutics
8.9. UCB Pharma
9. REFRACTORY EPILEPSY KEY PRODUCTS
9.1. Padsevonil
9.2. Seletracetam
9.3. Eslicarbazepine acetate
9.4. AQST-203
9.5. 2-Deoxy-D-glucose
9.6. Perampanel
9.7. Ganaxolone
9.8. Cannabidiol
9.9. Ataluren
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. REFRACTORY EPILEPSY - UNMET NEEDS
12. REFRACTORY EPILEPSY - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Refractory Epilepsy Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Refractory Epilepsy Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Refractory Epilepsy Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Refractory Epilepsy Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Refractory Epilepsy companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Refractory Epilepsy Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
UCB Pharma
Bial
Threshold Pharmaceuticals
Pfizer
Biocodex
Eisai
Marinus Pharmaceuticals
GW Pharmaceuticals
Eisai Co Ltd
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Refractory Epilepsy companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Refractory Epilepsy Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
UCB Pharma
Bial
Threshold Pharmaceuticals
Pfizer
Biocodex
Eisai
Marinus Pharmaceuticals
GW Pharmaceuticals
Eisai Co Ltd
